Octreotide Conjugates for Tumor Targeting and Imaging.

cryptophycin cytotoxic payloads imaging octreotide small molecule drug conjugates tumor targeting

Journal

Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003

Informations de publication

Date de publication:
07 May 2019
Historique:
received: 27 03 2019
revised: 02 05 2019
accepted: 03 05 2019
entrez: 10 5 2019
pubmed: 10 5 2019
medline: 10 5 2019
Statut: epublish

Résumé

Tumor targeting has emerged as an advantageous approach to improving the efficacy and safety of cytotoxic agents or radiolabeled ligands that do not preferentially accumulate in the tumor tissue. The somatostatin receptors (SSTRs) belong to the G-protein-coupled receptor superfamily and they are overexpressed in many neuroendocrine tumors (NETs). SSTRs can be efficiently targeted with octreotide, a cyclic octapeptide that is derived from native somatostatin. The conjugation of cargoes to octreotide represents an attractive approach for effective tumor targeting. In this study, we conjugated octreotide to cryptophycin, which is a highly cytotoxic depsipeptide, through the protease cleavable Val-Cit dipeptide linker using two different self-immolative moieties. The biological activity was investigated in vitro and the self-immolative part largely influenced the stability of the conjugates. Replacement of cryptophycin by the infrared cyanine dye Cy5.5 was exploited to elucidate the tumor targeting properties of the conjugates in vitro and in vivo. The compound efficiently and selectively internalized in cells overexpressing SSTR2 and accumulated in xenografts for a prolonged time. Our results on the in vivo properties indicate that octreotide may serve as an efficient delivery vehicle for tumor targeting.

Identifiants

pubmed: 31067748
pii: pharmaceutics11050220
doi: 10.3390/pharmaceutics11050220
pmc: PMC6571972
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : H2020 Marie Skłodowska-Curie Actions
ID : 642004
Organisme : Universität Bielefeld
ID : Open Access Publication Fund

Références

Eur J Nucl Med. 2001 Jul;28(7):836-46
pubmed: 11504080
Biopolymers. 2002;66(3):161-83
pubmed: 12385036
Bioconjug Chem. 2002 Nov-Dec;13(6):1238-43
pubmed: 12440858
Lung Cancer. 2003 Feb;39(2):197-9
pubmed: 12581573
Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S2-4
pubmed: 14508075
Mol Cancer Ther. 2004 Sep;3(9):1061-7
pubmed: 15367700
Mol Pharmacol. 2005 Jul;68(1):90-101
pubmed: 15855408
Invest New Drugs. 2005 Jun;23(3):213-24
pubmed: 15868377
Int J Gynecol Cancer. 2006 Jan-Feb;16(1):71-6
pubmed: 16445613
J Nucl Med. 2006 Mar;47(3):502-11
pubmed: 16513620
Bioorg Med Chem. 2006 Nov 15;14(22):7446-57
pubmed: 16877000
Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16436-41
pubmed: 17056720
Arch Pharm (Weinheim). 2009 Oct;342(10):577-83
pubmed: 19714674
Chemistry. 2009 Oct 26;15(42):11273-87
pubmed: 19760734
Org Lett. 2010 Mar 5;12(5):1064-7
pubmed: 20131817
J Med Chem. 2010 Aug 26;53(16):6188-97
pubmed: 20666484
J Org Chem. 2010 Oct 15;75(20):6953-60
pubmed: 20857920
Bioconjug Chem. 2012 Sep 19;23(9):1838-55
pubmed: 22871231
Beilstein J Org Chem. 2012;8:2060-6
pubmed: 23209540
Angew Chem Int Ed Engl. 2013 Jan 28;52(5):1384-402
pubmed: 23296451
J Med Chem. 2013 Mar 14;56(5):1853-64
pubmed: 23387527
Nat Prod Rep. 2013 Jul;30(7):924-40
pubmed: 23732943
Bioorg Med Chem Lett. 2015 Feb 15;25(4):864-8
pubmed: 25613677
Eur J Med Chem. 2015 Mar 26;93:55-63
pubmed: 25647428
J Pept Sci. 2015 Mar;21(3):186-200
pubmed: 25703117
J Med Chem. 2015 Nov 25;58(22):8751-61
pubmed: 26079148
Mol Pharm. 2015 Aug 3;12(8):3020-31
pubmed: 26086430
Int J Endocr Oncol. 2015;2(2):159-168
pubmed: 26257863
Mol Pharm. 2015 Dec 7;12(12):4290-300
pubmed: 26524088
Int J Pharm. 2016 Apr 11;502(1-2):98-106
pubmed: 26899980
Mol Cancer Ther. 2016 Dec;15(12):2926-2935
pubmed: 27609641
Oncotarget. 2016 Dec 27;7(52):86326-86338
pubmed: 27861145
Anal Bioanal Chem. 2017 Apr;409(10):2685-2696
pubmed: 28138743
Front Chem. 2017 Feb 23;5:8
pubmed: 28286746
J Pept Sci. 2017 Jul;23(7-8):514-531
pubmed: 28661555
Molecules. 2017 Aug 01;22(8):null
pubmed: 28763044
J Nucl Med. 2017 Sep;58(Suppl 2):61S-66S
pubmed: 28864614
Chem Rev. 2017 Oct 11;117(19):12133-12164
pubmed: 28898067
Bioconjug Chem. 2017 Dec 20;28(12):2921-2931
pubmed: 29211454
J Am Chem Soc. 2018 Feb 7;140(5):1617-1621
pubmed: 29342352
Bioconjug Chem. 2018 Apr 18;29(4):1155-1167
pubmed: 29481745
Mol Pharm. 2018 Jun 4;15(6):2297-2306
pubmed: 29684274
Mol Pharm. 2018 Jun 4;15(6):2289-2296
pubmed: 29715036
Beilstein J Org Chem. 2018 Jun 1;14:1281-1286
pubmed: 29977395
Future Med Chem. 2018 Sep 1;10(18):2201-2226
pubmed: 30043641
Am J Nucl Med Mol Imaging. 2018 Oct 20;8(5):311-331
pubmed: 30510849
ACS Omega. 2018 Nov 30;3(11):14726-14731
pubmed: 30533574
Pharmaceutics. 2019 Apr 01;11(4):null
pubmed: 30939768
Int J Pept Protein Res. 1994 Sep;44(3):215-22
pubmed: 7822097
Cancer Res. 1994 Jul 15;54(14):3779-84
pubmed: 7913408

Auteurs

Eduard Figueras (E)

Department of Chemistry, Organic and Bioorganic Chemistry, Bielefeld University, Universitätsstraße 25, DE-33615 Bielefeld, Germany. eduard.figueras@uni-bielefeld.de.

Ana Martins (A)

Department of Chemistry, Organic and Bioorganic Chemistry, Bielefeld University, Universitätsstraße 25, DE-33615 Bielefeld, Germany. ana_martins@exiris.it.
Exiris srl, Via di Castel Romano 100, IT-00128 Rome, Italy. ana_martins@exiris.it.

Adina Borbély (A)

Department of Chemistry, Organic and Bioorganic Chemistry, Bielefeld University, Universitätsstraße 25, DE-33615 Bielefeld, Germany. adina.borbely@uni-bielefeld.de.

Vadim Le Joncour (V)

Translational Cancer Medicine, Research Programs Unit, Haartmaninkatu 8, FI-00014 University Helsinki, Finland. vadim.lejoncour@helsinki.fi.

Paola Cordella (P)

Italfarmaco SpA, Via dei Lavoratori 54, IT-20092 Cinisello Balsamo, Italy. p.cordella@italfarmaco.com.

Raffaella Perego (R)

Italfarmaco SpA, Via dei Lavoratori 54, IT-20092 Cinisello Balsamo, Italy. r.perego@italfarmaco.com.

Daniela Modena (D)

Italfarmaco SpA, Via dei Lavoratori 54, IT-20092 Cinisello Balsamo, Italy. d.modena@italfarmaco.com.

Paolo Pagani (P)

Italfarmaco SpA, Via dei Lavoratori 54, IT-20092 Cinisello Balsamo, Italy. p.pagani@italfarmaco.com.

Simone Esposito (S)

IRBM SpA, Via Pontina km. 30,600, IT-00071 Pomezia, Italy. s.esposito@irbm.com.

Giulio Auciello (G)

IRBM SpA, Via Pontina km. 30,600, IT-00071 Pomezia, Italy. g.auciello@irbm.com.

Marcel Frese (M)

Department of Chemistry, Organic and Bioorganic Chemistry, Bielefeld University, Universitätsstraße 25, DE-33615 Bielefeld, Germany. marcel.frese@uni-bielefeld.de.

Paola Gallinari (P)

Exiris srl, Via di Castel Romano 100, IT-00128 Rome, Italy. paola_gallinari@exiris.it.

Pirjo Laakkonen (P)

Translational Cancer Medicine, Research Programs Unit, Haartmaninkatu 8, FI-00014 University Helsinki, Finland. pirjo.laakkonen@helsinki.fi.

Christian Steinkühler (C)

Exiris srl, Via di Castel Romano 100, IT-00128 Rome, Italy. christian_steinkuhler@exiris.it.
Italfarmaco SpA, Via dei Lavoratori 54, IT-20092 Cinisello Balsamo, Italy. christian_steinkuhler@exiris.it.

Norbert Sewald (N)

Department of Chemistry, Organic and Bioorganic Chemistry, Bielefeld University, Universitätsstraße 25, DE-33615 Bielefeld, Germany. norbert.sewald@uni-bielefeld.de.

Classifications MeSH